Biotech bears tend to outnumber the bulls at any given time -- and the present is no exception, with dealmaking activity down significantly in 2022, compared with the previous two years.
That's not say the amounts flowing into the industry are meager. Alternatives Watch has tracked more than 50 biotech financing rounds so far in the third quarter. Mainstream private market giants such as Andreessen Horowitz, Warburg Pincus, TPG and Section 32 (see chart below) have become active in the space, according to a recent AW Deal Watch analysis that also found a . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
